Intra-observer variation in the histopathological assessment of chronic viral hepatitis

Goldin, Robert D.; Goldin, Jonathan G.; Burt, Alastair D.; Dhillon, P A; Hübscher, S.G.; Wyatt, Judy; Patel, Neera K.

doi:10.1016/s0168-8278(96)80234-0

Cited by 156 publications

(95 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It's known that this type of necrosis is a finding frequently seen in acute/subacute or autoimmune hepatitis rather than CVH 25 . Confluent necrosis was not seen in any patient neither in our current study nor in the studies known in the literature 15,19 or seen in a few (1/363 cases) 1 . So, confluent necrosis was ignored by us.…”

Section: Discussioncontrasting

confidence: 79%

“…The most important problem in evaluation of different histological activity scoring systems in CVH is intraobserver and interobserver variation [14][15][16][17] . Common feature of the studies in the literature is the low interobserver and intraobserver error rate in staging; but this rate declines when scoring systems become more difficult to apply.…”

Section: Criteria For Treatment Successmentioning

confidence: 99%

See 1 more Smart Citation

The Relationship between Treatment Response and Histological Scoring Systems Applied in Chronic Hepatitis B

Abdullazade¹,

Kav²,

Gököz³

et al. 2017

Kafkas J Med Sci

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 79%

Section: Criteria For Treatment Successmentioning

confidence: 99%

The Relationship between Treatment Response and Histological Scoring Systems Applied in Chronic Hepatitis B

Abdullazade¹,

Kav²,

Gököz³

et al. 2017

Kafkas J Med Sci

View full text Add to dashboard Cite

“…A method of staging is proposed to reflect the typical fibrosis of steatohepatitis from zone 3 perisinusoidal fibrosis to bridging fibrosis to cirrhosis. Testing the reproducibility and ease of application of this system of grading and staging, as has been done for chronic hepatitis (26), awaits future studies.…”

Section: Ajg -September 1999mentioning

confidence: 99%

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

Brunt¹,

Janney²,

Bisceglie³

et al. 1999

The American Journal of Gastroenterology

1,448

2,003

View full text Add to dashboard Cite

“…This definition of histological response has been recommended in chronic hepatitis C. 28 Using a Ն2-point reduction in necro-inflammatory score as the response definition should minimize the impact of the 1-point variation, which would be anticipated to occur owing to observer variability and liver sampling. 29 Fibrosis and necro-inflammatory activity were also compared for each biopsy pair (blinded for sequence) to assess whether one showed more severe hepatitis and/or more fibrosis (ranked response).…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Positive (Precore Mutant) Chronic Hepatitis Befficacy of Lamivudine in Patients With Hepatitis B E Antigen-Negative/Hepatitis B Virus Dna-Posi

et al. 1999

Self Cite

View full text Add to dashboard Cite

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60) or placebo for 26 weeks (n ‫؍‬ 65). Patients who were HBV DNA positive at week 24 were withdrawn at week 26. The primary efficacy endpoint was loss of serum HBV DNA plus normalization of alanine transaminase (ALT) at week 24. A significantly higher proportion of patients receiving lamivudine (63%) had a complete response at week 24 compared with patients receiving placebo (6%) (P F .001). Secondary efficacy parameters included histological response from baseline to week 52 in the lamivudine-treated patients. At week 52, 60% of lamivudine-treated patients with liver biopsy specimens available showed histological improvement (H2-point reduction in Knodell necro-inflammatory score), 29% showed no change, and 12% worsened. In a ranked assessment of pretreatment and post-treatment biopsy pairs 11% improved, 86% showed no change, and 2% worsened in fibrosis. At week 52, 27% of patients receiving lamivudine had YMDD (tyrosine-methionine-aspartate-aspartate amino acid motif of HBV polymerase) variant HBV. The incidence of adverse events and laboratory abnormalities was similar in both groups. In conclusion, lamivudine treatment results in a significant virological and biochemical improvement compared with placebo, induces an improvement or no change in histology in most patients, and is well tolerated. The response to lamivudine therapy in HBeAg-negative patients is similar to the response reported in previous studies of patients with HBeAg-positive chronic hepatitis B. (HEPATOLOGY 1999;29:889-896.)

show abstract

Intra-observer variation in the histopathological assessment of chronic viral hepatitis

Cited by 156 publications

References 8 publications

The Relationship between Treatment Response and Histological Scoring Systems Applied in Chronic Hepatitis B

The Relationship between Treatment Response and Histological Scoring Systems Applied in Chronic Hepatitis B

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

Contact Info

Product

Resources

About